Royal Bank of Canada Has $20.28 Million Stock Holdings in United Therapeutics Corporation $UTHR

Royal Bank of Canada boosted its position in shares of United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 99.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 65,789 shares of the biotechnology company's stock after purchasing an additional 32,867 shares during the period. Royal Bank of Canada owned 0.15% of United Therapeutics worth $20,281,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in United Therapeutics by 0.3% during the first quarter. Vanguard Group Inc. now owns 4,457,135 shares of the biotechnology company's stock valued at $1,374,001,000 after purchasing an additional 15,312 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in United Therapeutics by 0.7% during the first quarter. Dimensional Fund Advisors LP now owns 624,711 shares of the biotechnology company's stock valued at $192,571,000 after purchasing an additional 4,145 shares during the last quarter. Assetmark Inc. boosted its position in United Therapeutics by 20.8% during the first quarter. Assetmark Inc. now owns 518,450 shares of the biotechnology company's stock valued at $159,823,000 after purchasing an additional 89,290 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its position in United Therapeutics by 22.5% during the first quarter. Caisse DE Depot ET Placement DU Quebec now owns 477,757 shares of the biotechnology company's stock valued at $147,278,000 after purchasing an additional 87,664 shares during the last quarter. Finally, Janus Henderson Group PLC boosted its position in United Therapeutics by 1.9% during the fourth quarter. Janus Henderson Group PLC now owns 468,996 shares of the biotechnology company's stock valued at $165,490,000 after purchasing an additional 8,577 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $394.62 on Tuesday. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $436.95. The stock's 50-day moving average is $309.83 and its two-hundred day moving average is $305.60. The firm has a market cap of $17.80 billion, a P/E ratio of 15.40, a price-to-earnings-growth ratio of 6.11 and a beta of 0.62.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts' consensus estimates of $6.80 by ($0.39). The business had revenue of $798.60 million during the quarter, compared to the consensus estimate of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The company's revenue for the quarter was up 11.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $5.85 earnings per share. On average, equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on UTHR shares. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $500.00 and gave the company a "buy" rating in a research report on Friday. Morgan Stanley reduced their price objective on United Therapeutics from $348.00 to $328.00 and set an "equal weight" rating for the company in a research report on Thursday, July 10th. Wells Fargo & Company lifted their price objective on United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Bank of America raised their target price on United Therapeutics from $314.00 to $463.00 and gave the company a "neutral" rating in a report on Tuesday, September 2nd. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of United Therapeutics in a report on Thursday, August 14th. Nine research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $429.62.

Insiders Place Their Bets

In other news, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $385.21, for a total value of $4,237,310.00. Following the transaction, the executive vice president directly owned 36,781 shares in the company, valued at approximately $14,168,409.01. The trade was a 23.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total value of $879,225.60. Following the completion of the transaction, the director owned 19,384 shares in the company, valued at $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 106,181 shares of company stock valued at $35,537,239. Company insiders own 10.30% of the company's stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.